GLP-1 and Fertility: What to Know When You're Trying to Get Pregnant During Treatment

Starting a GLP-1 medication can feel like turning a page. For many women, the months that follow bring real changes — not just on the scale, but in how they feel in their own skin. And then comes a question that catches a lot of people off guard: what happens if I want to get pregnant while using this?

You're not alone in asking. Thousands of women in their reproductive years are on medications like Ozempic, Wegovy, Mounjaro, or Saxenda, and a growing number of them are thinking about starting or expanding a family. The conversation between GLP-1 treatment and fertility is real, and it deserves a straight answer grounded in what science actually shows.

This post walks through what we know — and what we don't — about how these medications interact with reproduction, what the current medical guidance says, and exactly what you can do to plan ahead.

---

How GLP-1 Medications Work in the Body

Before looking at the fertility connection, it helps to understand what these drugs actually do.

GLP-1 agonists are medications that mimic a hormone your body already produces. Semaglutide, liraglutide, and tirzepatide all work by binding to GLP-1 receptors throughout the body. They slow down stomach emptying, regulate blood sugar, and send satiety signals to the brain. The result is less hunger and steadier glucose levels.

Here's the part that matters for fertility: GLP-1 receptors aren't only found in the gut and pancreas. They also exist in ovarian tissue, the uterus, and other parts of the reproductive system. That means the hormone these medications imitate has a direct line to some of the same structures involved in ovulation and pregnancy. It doesn't work like a sex hormone, but it does communicate with the endocrine system that governs reproduction.

---

The Indirect Path: Weight Loss and Fertility

The most significant way GLP-1 affects fertility isn't direct. It works through weight loss.

Obesity disrupts the reproductive system in several ways. Extra adipose tissue increases insulin resistance, which throws off the hormonal signals that govern ovulation. Many women with obesity or excess weight experience irregular cycles, anovulatory cycles, and altered levels of estrogen and androgens. All of that makes it harder to conceive.

When GLP-1 leads to meaningful weight loss, those problems often improve. A drop of 5 to 10 percent of body weight can be enough to restart ovulation in women who previously had anovulatory cycles. Research shows ovulation rates between 30 and 50 percent in women with PCOS after this kind of weight reduction.

For women with PCOS specifically, the benefits go further. Insulin resistance and elevated androgen levels tend to improve with the weight loss driven by GLP-1 therapy. That creates a more favorable hormonal environment for ovulation to occur.

One thing worth noting: fertility can return faster than expected once the body starts ovulating again. If preventing pregnancy is the goal, that matters. Couples who aren't planning to conceive should discuss reliable contraception with their doctor during the GLP-1 treatment phase and the pause period that may follow.

Some women undergoing fertility treatments have reported better responses to ovulation induction protocols after starting GLP-1, though this is still an area where more data is accumulating.

---

What the Science Says About GLP-1 and Reproductive Hormones

Researchers have been studying the direct effects of GLP-1 on ovarian tissue for several years now.

Animal studies show that GLP-1 can modulate estrogen production and influence the function of granulosa cells, which support egg development. In humans, studies have documented reductions in androgen levels — specifically testosterone — in women with PCOS after 12 to 24 weeks of treatment with semaglutide or tirzepatide. Lower androgens mean a less hostile environment for ovulation.

Some fertility protocols are now combining GLP-1 agonists with agents like metformin or clomiphene, and early results in controlled settings have been promising. But it's important to note where the evidence is thin.

Most of the data we have comes from women with obesity or PCOS. There is far less information about women with no underlying metabolic or reproductive conditions who happen to be using GLP-1. That means some of the conclusions don't necessarily apply across the board.

On the question of ovarian reserve — the total supply of viable eggs — the current data is limited and inconclusive. So far, there is no evidence that GLP-1 medications cause damage to ovarian reserve, but researchers are still gathering long-term follow-up data.

---

Getting Pregnant While on Treatment: What We Know and Don't Know

The direct answer to "can I get pregnant while on GLP-1?" has evolved.

In September 2024, the FDA updated the labeling for semaglutide. The previous guidance carried an absolute contraindication against pregnancy. The revised label removed that and now recommends pausing the medication at least two months before attempting to conceive. That change reflects a growing body of evidence that these medications don't appear to cause birth defects in humans, though human data remains relatively limited.

The two-month figure relates to how long semaglutide stays in the body. Its half-life is approximately one week, which means it takes about two months for the drug to clear to levels considered negligible.

Animal studies did show fetal abnormalities at high doses of semaglutide, but those doses were many times higher than what humans receive, and the effects appeared linked to severe maternal malnutrition. That context matters when evaluating what those findings mean for people.

In real-world reports, many women have become pregnant without knowing they were exposed to GLP-1 very early in gestation, and their babies were born healthy. Those anecdotes are encouraging, but they are not a clinical trial. They don't give us the statistical certainty that researchers need to make firm claims.

The practical consensus among physicians is clear: if pregnancy is the goal, plan for it. That means pausing the medication before trying to conceive, not discovering a pregnancy while still on the drug.

---

A Practical Plan for Women Who Are Trying to Conceive

Here's what the process generally looks like, though your doctor is the one who can tailor it to your specific situation.

Start by having the conversation with your physician while you're still on GLP-1. Bring up your plans to conceive and ask how to approach the transition safely. Don't stop the medication on your own.

When the time comes to pause, most guidelines suggest stopping at least four to eight weeks before attempting to conceive. Some doctors prefer the full two months, especially with semaglutide, because of its longer half-life.

Use a reliable form of birth control during the pause period. Fertility can return more quickly than anticipated once ovulation resumes, so this isn't the time to leave it to chance.

After pausing, pay attention to your cycle. Tracking changes in your menstrual pattern can give you early clues that ovulation has returned. If your cycles become regular again, that's a positive sign.

Before you start trying, ask your doctor about hormonal testing. Baseline checks of FSH, LH, estrogen, and progesterone can help establish where things stand and guide next steps.

Ongoing monitoring matters. Most women who achieve weight loss with GLP-1 are able to conceive naturally, but the process goes more smoothly with proper medical support. Women with PCOS or insulin resistance often benefit from working with an endocrinologist or reproductive specialist during this phase.

---

What to Do If You Discover You're Pregnant While on GLP-1

Finding out you're pregnant while still on medication is stressful, but the first thing to know is that there's no need to panic.

Call your doctor right away. The standard recommendation is to discontinue the GLP-1 medication as soon as the pregnancy is confirmed. Your healthcare provider will guide you through that process.

Early first-trimester exposure — meaning you were taking the medication before you knew you were pregnant — has not shown a clear pattern of harm in the data collected so far. But because the evidence base is still limited, your doctor will likely recommend closer monitoring throughout the pregnancy.

If you were on a higher dose, that may prompt more attentive follow-up, though the specifics depend on your individual clinical picture.

After delivery, most GLP-1 medications are not recommended during breastfeeding due to insufficient safety data. Planning the return to treatment with your doctor after delivery is something worth discussing well before the baby arrives.

For next time, the lesson is simple: plan the pause with your doctor ahead of any attempt to conceive. That gives you the best possible starting point for a healthy pregnancy.

---

This post is for informational purposes only and does not replace personalized medical advice. Always consult your healthcare provider about your specific situation.

---

Tracking your cycle and symptoms during the fertility planning process makes a real difference. The Ozempro app lets you log your menstrual cycle, ovulation signs, medication doses, and any symptoms in one place, giving you and your doctor a clearer picture when it's time to make decisions about pausing or resuming GLP-1. You can start by clicking here for a personalized assessment.

Keeping a detailed record of your cycles, energy levels, and any changes in your pattern is one of the most useful steps you can take while preparing to conceive. The app makes that record-keeping straightforward, so you arrive at your medical appointments with actual data instead of rough estimates.

When the time comes to discuss pausing your GLP-1 medication with your doctor, having weeks or months of cycle and symptom history to share can make that conversation much more productive. Ozempro is designed to support exactly that kind of informed, data-driven dialogue with your healthcare team.